Remus Pharmaceuticals Approves NSE Emerge Migration To NSE And BSE Main Boards

Board approved migration from NSE Emerge to the NSE and BSE Main Boards, subject to shareholder, exchange and regulatory approvals; also approved a Dominican Republic subsidiary. Main-board migration could broaden investor access, while the subsidiary extends Remus's Latin America pharmaceutical distribution expansion beyond existing markets. Remus will hold at least 51% through cash subscription; incorporation cost, funding quantum, timeline and regulatory execution details remain undisclosed.